Effect of calcitonin gene-related peptide receptor antagonism on the systemic blood pressure responses to mechanistically diverse vasomodulators in conscious rats

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 5, 2010, Pages 518-525

  Lynch Jr , Joseph J ^a   Detwiler, Theodore J ^a   Kane, Stefanie A ^a   Regan, Christopher P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

calcitonin gene related peptide; CGRP8 37; dihydroergotamine; sumatriptan

Indexed keywords

ADENOSINE; ANGIOTENSIN II; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE[8-37]; DIHYDROERGOTAMINE; GLYCERYL TRINITRATE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; SUMATRIPTAN;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CAROTID ARTERY FLOW; CONSCIOUSNESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEART HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD PRESSURE; CALCITONIN GENE-RELATED PEPTIDE; CAROTID ARTERIES; DIHYDROERGOTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMICS; MALE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; REGIONAL BLOOD FLOW; SUMATRIPTAN; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 78650763344     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f5d414     Document Type: Article

References (47)

1. 1B/1D agonists) in the acute treatment of migraine. Headache. 2004;44:414-425.
2. Narbone MC, Abbate M, Gangemi S. Acute drug treatment of migraine attack. Neurol Sci. 2004;25(Suppl 3):S113-S118.
3. Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. Am J Med. 2005;118(Suppl 1):36S-44S.
4. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006;46(Suppl 4): S171-S181.
5. Hall GC, Brown MM, Mo J, et al. Triptans in migraine. The risks of stroke, cardiovascular disease and death in practice. Neurology. 2004;62: 563-568.
6. Galer BS, Lipton RB, Solomon S, et al. Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache. 1991;31: 446-450.
7. Brown EG, Endersby CA, Smith RN, et al. The safety and tolerability of sumatriptan: an overview. Eur Neurol. 1991;31:339-344.
8. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache. 1990;30: 334-339.
9. Olesen J, Diener H-C, Husstedt IW, et al; for the BIBN4096BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Eng J Med. 2004;350:1104-1110.
10. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372:2115-2123.
11. Ho TW, Mannix LK, Fan X, et al; on behalf of the MK-0974 Protocol 004 Study Group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70:1304-1312.
12. Connor KM, Shapiro RE, Diener H-C, et al.Randomized controlled trial of telcagepant for the acute treatment of migraine. 2009;73:970-977.
13. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004;84:903-934.
14. (8-37). Am J Physiol. 1989;256: E331-E335.
15. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129:420-423.
16. Gardiner SM, Compton AM, Kemp PA, et al. Human a-calcitonin gene-related peptide (CGRP)-(8-37), but not-(28-37), inhibits carotid vasodilator effects of human a-CGRP in vivo. Eur J Pharmacol. 1991; 199:375-378.
17. Shen Y-T, Pittman TJ, Buie PS, et al. Functional role of a-calcitonin gene-related peptide in the regulation of the cardiovascular system. J Pharmacol Exp Ther. 2001;298:551-558.
18. Shen Y-T, Mallee JJ, Handt LK, et al. Effects of inhibition of a-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure. J Cardiovasc Pharmacol. 2003;42:656-661.
19. Kapoor K, Arulmani U, Heiligers JPC, et al. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. Eur J Pharmacol. 2003;475:69-77.
20. Arulmani U, Schuijt MP, Heiligers JPC, et al. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on a-CGRP-induced regional haemodynamic changes in anaesthetised rats. Basic Clin Pharmacol Toxicol. 2004;94:291-297.
21. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anesthetized dogs. Br J Pharmacol. 1989;96:83-90.
22. Van Gelderen EM, Du XY, Schoemaker RG, et al. Carotid blood flow distribution, haemodynamics, and inotropic responses following calcito-nin gene-related peptide in the pig. Eur J Pharmacol. 1995;284:51-60.
23. 2-adrenoceptors. Br J Pharmacol. 1999; 126:585-594.
24. Tfelt-Hansen P, Saxena PR, Dahlöf C, et al. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain. 2000; 123:9-18.
25. Fisher LA, Kikkawa DO, Rivier JE, et al. Stimulation of noradrenergic sympathetic outflow by calcitonin gene-related peptide. Nature. 1983; 305:534-536.
26. Kawasaki H, Nuki C, Saito A, et al. Adrenergic modulation of calcitonin gene-related peptide (CGRP)-containing nerve-mediated vasodilation in the rat mesenteric resistance vessel. Brain Res. 1990;506:287-290. (Pubitemid 20031610)
27. Kawasaki H, Takenaga M, Araki H, et al. Angiotensin inhibits neurotransmission of calcitonin gene-related peptide-containing vasodilator nerves in mesenteric artery of spontaneously hypertensive rats. J Pharmacol Exp Ther. 1998;284:508-515.
28. Itabashi A, Kashiwabara H, Shibuya M, et al. The interaction of calcitonin gene-related peptide with angiotensin II on blood pressure and renin release. J Hypertens. 1988;6(Suppl 4):S418-S420.
29. Zulli A, Ye B, Wookey PJ, et al. Calcitonin gene-related peptide inhibits angiotensin II-mediated vasoconstriction in human radial arteries: role of the Kir channel. J Thorac Cardiovasc Surg. 2008;136:370-375.
30. Booth BP, Tabrizi-Fard MA, Fung H-L. Calcitonin gene-related peptide-dependent vascular relaxation of rat aorta. An additional mechanism for nitroglycerin. Biochem Pharmacol. 2000;59:1603-1609.
31. Zhou Z-H, Deng H-W, Li Y-J. The depressor effect of nitroglycerin is mediated by calcitonin gene-related peptide. Life Sci. 2001;69:1313-1320.
32. 1- adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2008;376:321-330.
33. De Metz JE, van Zwieten PA. Differential effects of dihydroergotamine on the circulatory actions of arterial and venous dilators in the rat. J Cardiovasc Pharmacol. 1981;3:217-227.
34. Müller H, Glusa E, Markwardt F. Dual effect of dihydroergotamine at vascular 5-hydroxytryptamine receptors in pithed rats. Pharmacology. 1988;37:248-253.
35. 1D (BRL15572) receptor antagonists. Eur J Pharmacol. 1998;362:69-72.
36. 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroer-gotamine. Eur J Pharmacol. 2004;484:287-290.
37. 2A receptors mediating constriction of the canine internal carotid circulation. Br J Pharmacol. 2001;132:983-990.
38. 1Dß receptor. Mol Pharmacol. 1992;41:1-7.
39. 1B receptors. Nature. 1992;360:161-163.
40. 1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther. 2000;68:418-426.
41. 1B/D receptor agonists in the normotensive rat. Br J Pharmacol. 1998;123:205-214.
42. Gras J, Cardelús I, Llenus J, et al. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine. Eur J Pharmacol. 2000;410:53-59.
43. Roquebert J, Grenié B. Heart rate lowering effects of dihydroergotamine in rats. Arch Int Pharmacodyn. 1987;290:25-35.
44. 1-adrenergic antagonist activity of ergotamine and dihydroergotamine in rats. Arch Int Pharmacodyn. 1986;284:30-37.
45. Diener H-C, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs. 2001;10:1831-1845.
46. Lu JT, Son Y-J, Lee J, et al. Mice lacking a-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol Cell Neurosci. 1999;14:99-120.
47. Oh-Hashi Y, Shindo T, Kurihara Y, et al. Elevated sympathetic nervous activity in mice deficient in aCGRP. Circ Res. 2001;89:983-990.